Equipoise is the popularly referenced brand name for the veterinary injectable steroid boldenone undecylenate. Specifically it is a derivative of testosterone, which exhibits strong anabolic and moderately androgenic properties. The undecylenate ester greatly extends the activity of the drug (the undecylenate ester is only one carbon atom longer than decanoate), so that clinically injections would need to be repeated every three or four weeks. In veterinary medicine Equipoise is most commonly used on horses, exhibiting a pronounced effect on lean bodyweight, appetite and general disposition of the animal. This compound is also said to shows a marked ability for increasing red blood cell production, although there should be no confusion that this is an effect characteristic of newly all anabolic/androgenic steroids. The favorable properties of this drug are greatly appreciated by athletes, Equipoise being a very popular injectable in recent years. It is considered by many to be a stronger, slightly more androgenic Deca-Durabolin . It is generally cheaper, and could replace Deca in most cycles without greatly changing the end result.Equipoise Raw material
Side effects
The side effects associated with Equipoise are generally mild. The
structure of boldenone does allow it to convert into estrogen, but it
does not have an extremely high affinity to do so. To try and quantify
this we can look toward aromatization studies, which suggest that its
rate of estrogen conversion should be roughly half that of
testosterone’s. The tendency to develop a noticeable amount of water
retention with this drug would therefore be slightly higher than that
with Deca-Durabolin (with an estimated 20°/a conversion), but much less
than what would be expected with a stronger agent such as Testosterone.
While one does still have a chance of encountering an estrogen related
side effect as such when using this substance, it is not a common
problem when taken at a moderate dosage level. Gynecomastia might
theoretically become a concern, but is usually only heaved of with very
sensitive individuals or (again) those venturing high in dosage. Should
estrogenic effects become troublesome, the addition of Nolvadex and/or
Proviron should of course make the cycle more tolerable. An
antiaromatase such as Cytadren or Arimidex would be stronger options,
however probably not indicated with a mild drug as such.
Equipoise can also produce distinct androgenic side effects. Incidences
of oily skin, acne, increased aggression and hair loss are likewise all
possible with this compound, although will typically be related to the
use of higher doses. Women in fact find this drug quite comfortable,
virilization symptoms usually unseen when taken at low doses. Boldenone
does reduce to a more potent androgen (dihydroboldenone) via the 5alpha
reductase enzyme (which produces DHT from testosterone), however its
affinity for this interaction in the human body is low to nonexistent”.
We therefore cannot consider the reductase inhibitor Proscar to be of
much use with Equipoise, as it would be blocking what is at best an
insignificant path of metabolism for the steroid. And although this drug
is relatively mild, it may still have a depressive effect on endogenous
testosterone levels. A combination of HCG and Clomid ®/Nolvadex may
likewise be needed at the conclusion of each cycle to avoid a “crash”,
particularly when running long in duration.
